About: http://data.cimple.eu/news-article/2972748ac6d0e92d082ce0b8459fc8515640501287178c361d2bbb93     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

AttributesValues
rdf:type
schema:articleBody
  • Germany's BioNTech, one of the lead contenders in the race to develop a coronavirus vaccine, said Thursday it was buying a new manufacturing site to quickly ramp up production once its vaccine gets the green light. The firm said it had agree to acquire a "state-of-the-art" production facility in the western German city of Marburg from Swiss pharma giant Novartis. "This acquisition reflects BioNTech's commitment to significantly expanding its manufacturing capacity in order to supply a potential vaccine worldwide upon authorisation or approval," finance chief Sierk Poetting said in a statement. The Marburg site will scale up BioNTech's Covid-19 vaccine production capacity by up to 750 million additional doses per year, or over 60 million doses per month, "once fully operational", the statement added. No financial details were revealed. The deal is expected to close in the fourth quarter of 2020, and the 300 Novartis staff at the site will switch to working for BioNTech. Mainz-based BioNTech is teaming up with US behemoth Pfizer to develop a coronavirus vaccine using new technology based on mRNA, a type of genetic material never before used to make a vaccine. They already have one vaccine candidate in the late-stage Phase 3 trial that is currently being tested on around 30,000 volunteers. Just eight other vaccine candidates globally have reached this stage so far. The European Union, the United States and several other countries have already announced large contracts to secure millions of doses of the possible BioNTech-Pfizer vaccine once it clears all the necessary regulatory hurdles. Ahead of the Marburg acquisition, BioNTech said it planned to supply up to 100 million doses by the end of 2020 if its vaccine is successful, and 1.3 billion doses by the end of 2021. Next year's number is now expected to be "significantly" higher, a spokeswoman told AFP. The Marburg purchase comes just days after BioNTech received a 375-million-euro ($440-million) funding boost from the German government . mfp/hmn/cdw
schema:headline
  • BioNTech buys German site to ramp up Covid-19 vaccine production
schema:mentions
schema:author
schema:datePublished
http://data.cimple...sPoliticalLeaning
http://data.cimple...logy#hasSentiment
http://data.cimple...readability_score
http://data.cimple...tology#hasEmotion
Faceted Search & Find service v1.16.115 as of Oct 09 2023


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 5 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software